Evotec and Roche terminate proof-of-concept study with EVT101
Hamburg/Basel – Evotec AG and its partner Roche have terminated the first proof-of-concept study with Evotec’s NR2B sub-type selective NMDA antagonist EVT 101 in treatment-resistant depression.The firms said the move was motivated by difficulties in recruiting patients under the current study protocol, resulting in the possibility of inconclusive results. Furthermore the companies, which collaborate under a potential US$300m deal in phase II development of the drug, said the programme was already delayed due to difficulties in conducting it in treatment resistant depression, the need to sharpen the toxicology profile and a potential requirement for an altered dosage scheme. The clinical co-development of the compound, which Evotec in-licensed from Roche in development stage, was key to the alliance between Evotec and Roche signed in 2009 that was 100% funded by Roche. Evotec retains all rights in the EVT100 series, particularly the back-up compound EVT103, and will enter into partnering discussions for these assets in another clinical development partnership. Recently the Hamburg based firm announced an 54% increase in Q1/2011 (EUR15.1) compared to Q1/2010 (EUR9.8), mainly due to revenues from research alliances.